Table 5.

Changes (%) in Markers of Bone Turnover with Testosterone Therapy According to the rs1062033 and rs70518 Polymorphisms of the CYP19A1.

Rs1062033	CC	CG	GG	P
CTX
6 months	−33.86±34.02	−17.45±35.53	−9.0±92.18	0.29
12 months	−16.00±50.49	0.79±42.25	−3.85±53.62	0.40
18 months	−14.49±51.05	5.89±48.82	48.96±98.42a,b	0.008
Osteocalcin
6 months	−2.61±59.33	1.61±56.36	−4.61±57.91	0.93
12 months	4.07±96.58	8.90±91.33	7.91±64.62	0.98
18 months	−28.96±144.48	−20.59±128.37	33.59±118.59	0.30
Sclerostin
6 months	−8.19±32.64	5.35±32.67	4.92±35.41	0.23
12 months	2.10±42.21	4.70±34.06	16.02±47.99	0.50
18 months	13.75±47.56	7.44±42.67	15.72±41.30	0.77
Rs700518	AA	AG	GG	P
CTX
6 months	−37.42±19.66	−18.13±40.10	−8.59±94.91	0.24
12 months	−17.31±55.44	−0.50±40.68	−6.03±5.32	0.44
18 months	−9.75±13.80	3.35±9.64	41.47±16.33c,d	0.05
Osteocalcin
6months	10.28±56.76	−6.77±58.06	−3.01±56.26	0.53
12 months	20.56±104.95	−4.41±83.19	17.79±71.62	0.49
18 months	−7.37±112.06	−31.22±148.00	12.40±133.13	0.28
Sclerostin
6 months	−6.60±32.95	3.83±33.13	0.52±35.58	0.51
12 months	7.98±43.83	1.77±34.44	14.57±48.09	0.54
18 months	23.58±48.20	3.75±41.71	15.09±41.54	0.21

Means±SD, CTX: C-telopeptide,

^ap<0.05 GG vs CC,

^bp<0.05 GG vs CG,

^cp<0.05 GG vs. AA and

^dp<0.05 GG vs. AG.